文献速递妇科

复发性上皮性卵巢癌患者延长使用聚乙二醇脂质体多柔比星的疗效与毒性

Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2020-06-01

回顾性分析69例接受超过7个周期聚乙二醇脂质体多柔比星(PLD)的复发性上皮性卵巢癌患者,中位11.0个周期、中位累积剂量400 mg/m2。41例(59.4%)获临床获益,中位无进展生存期13.0个月(95%CI 10.7–15.2),中位总生存期40.2个月(95%CI 30.0–49.0),3/4级毒性发生率31.9%。

要点

  • 延长PLD治疗中位11.0个周期,59.4%患者获临床获益,3/4级毒性发生率31.9%。
  • 中位无进展生存期13.0个月,中位总生存期40.2个月。
  • 铂敏感与铂耐药患者的无进展生存期和总生存期均无显著差异。

核心结论

  • 在接受超过7个周期PLD的铂敏感和铂耐药复发性上皮性卵巢癌患者中,约一半获得持续临床获益且毒性可接受,PLD可考虑用于初始有反应且至少疾病稳定的患者的延长使用和维持治疗。

研究设计与样本

  • 回顾性识别接受超过7个周期PLD的复发性上皮性卵巢癌女性,疗效按RECIST 1.1评估,无进展生存期和总生存期自PLD开始计算,毒性按CTCAE v5.0评估,采用Kaplan-Meier法和Cox比例风险模型分析。

主要发现

  • 69例患者接受PLD中位11.0个周期(范围7–115),中位累积剂量400 mg/m2(范围210–4600 mg/m2);29.0%(n=20)为铂敏感疾病,71.0%(n=49)为铂耐药疾病。
  • 观察到的3/4级毒性发生率为31.9%(n=22),其中皮肤毒性最常见(n=13;18.8%)。
  • 41例(59.4%)获临床获益:完全缓解17.4%(n=12),部分缓解13.0%(n=9),疾病稳定29.0%(n=20)。
  • 所有患者中位无进展生存期13.0个月(95%CI 10.7–15.2),铂敏感与铂耐药无显著差异(15.9个月 vs 12.3个月;HR 1.15,95%CI 0.66–2.00;p=.61)。
  • 延长PLD治疗中位总生存期40.2个月(95%CI 30.0–49.0),铂敏感与铂耐药无显著差异(44.7个月 vs 33.3个月;HR 1.85,95%CI 0.91–3.78;p=.07);治疗期间发生4例(5.8%)口腔鳞状细胞癌。

临床怎么用

  • 作者认为,对于初始有反应且至少疾病稳定的复发性上皮性卵巢癌患者,PLD可考虑延长使用和维持治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and toxicity of extended duration pegylated liposomal doxorubicin (PLD) in women with recurrent epithelial ovarian carcinoma (rEOC). METHODS: Women with rEOC who received >7 cycles of PLD were retrospectively identified. Response was determined by RECIST 1.1. Progression free survival (PFS) and overall survival (OS) were calculated from PLD initiation. Toxicity was assessed by CTCAE v5.0. Kaplan Meier estimates and Cox proportional hazards were used to evaluate differences in time to recurrence or survival. RESULTS: 69 patients with rEOC received a median of 11.0 cycles (range, 7-115) at a median cumulative dose of 400 mg/m2 (range, 210-4600 mg/m2); 29.0% (n = 20) had platinum sensitive and 71.0% (n = 49) had platinum resistant disease. Of the observed grade ¾ toxicities (31.9%; n = 22), dermatologic were most frequent (n = 13; 18.8%). 41 women (59.4%) experienced clinical benefit; complete response in 17.4% (n = 12), partial response in 13.0% (n = 9) and stable disease in 29.0% (n = 20). Median PFS for all patients was 13.0 months (95% CI, 10.7, 15.2); there were no significant differences between platinum sensitive versus resistant disease (15.9 months vs. 12.3 months; HR 1.15, 95% CI, 0.66, 2.00; p = .61). With extended duration PLD, median OS was 40.2 months (95% CI 30.0, 49.0); no significant differences were noted for platinum sensitive versus resistant disease (44.7 months vs. 33.3 months; HR 1.85, 95% CI, 0.91, 3.78; p = .07). Four cases (5.8%) of oral squamous cell carcinoma occurred during treatment. CONCLUSIONS: Among women with both platinum sensitive and resistant rEOC who received >7 cycles of PLD, approximately one-half experienced sustained clinical benefit with acceptable toxicity. PLD may be considered for extended usage and maintenance in initially responding women with rEOC at least stable disease.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chambers LM, Pendlebury A, Rose PG, et al. Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer. Gynecol Oncol. 2020. PMID: 32499072. doi:10.1016/j.ygyno.2020.04.708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。